OCUS Innovation

What OCUS Innovation does

OCUS Innovation Limited is a Hong Kong-registered private clinical research organization that conducts biopharmaceutical research on atropine-based ophthalmic treatments for childhood myopia progression. The company's core product portfolio centers on three atropine concentrations — 0.01%, 0.025%, and 0.05% — evaluated in two parallel programs: a retrospective longitudinal cohort study in Hong Kong (2016–2023, conducted with HKU and CUHK Eye Centres) evaluating 0.01% atropine safety and tolerability, and the MODERATO trial, a randomized, blinded, placebo-controlled study launched in March 2025 that tests 0.025% and 0.05% atropine in 234 European children aged 3–17 across 9 countries.

The company operates through three regional entities — OCUS HK (headquartered at Hong Kong Science Park), OCUS UK, and OCUS IRELAND (Dublin office) — coordinating clinical research with academic and hospital partners including Moorfields Eye Hospital, Aston University, University College Cork, and university hospitals in Spain, Italy, Poland, and Albania. Its governance is entirely academic, with a four-member board comprising professors of pharmacology and ophthalmology from HKU and CUHK, plus a pharmaceutical industry executive from Jacobson Pharma Corporation.

The revenue model is clinical research services and potential licensing of research findings, not commercial product sales. The company targets pediatric ophthalmology patients (children with myopia of at least -0.75D) and serves institutional research partners. Pricing is not publicly disclosed. No external venture capital, institutional investors, or parent company have been identified, and the organization appears self-funded through its academic founders.

Name

OCUS Innovation

Legal name

OCUS INNOVATION LIMITED

Website

https://ocus-inno.com

Company type

Private

Founded year

2022

Operating status

Operating

Short description

OCUS Innovation is a clinical research organization conducting trials on atropine eye drop formulations (0.01%, 0.025%, 0.05%) to slow myopia progression in children, operating the MODERATO trial across 9 European countries and a retrospective study in Hong Kong.

Ownership category

akta.pro rank

Product category

Ophthalmic Clinical Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro industry

PRIMARYHLAIACAK

Ophthalmology Specialty Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Specialty Pharmaceuticals

SECONDARYHLAIAAAL

Ophthalmology Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

• Ophthalmic clinical research
• Myopia control trials
• Atropine formulation development
• Pediatric ophthalmology studies
• Clinical trial management

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D

Revenue model

1. Clinical Research Services: OCUS Innovation conducts clinical trials for pharmaceutical companies and research institutions investigating atropine-based myopia treatments. Revenue appears to be derived from research collaborations, trial management services, and potential licensing of research findings.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

OCUS Innovation conducts biopharmaceutical clinical research focused on atropine-based ophthalmic formulations for managing childhood myopia. The company operates the multinational MODERATO trial across nine European countries evaluating 0.025% and 0.05% atropine eye drops, and runs a retrospective longitudinal study on 0.01% atropine in collaboration with Hong Kong universities. Services span clinical trial design, site management, and evidence generation across its OCUS HK, OCUS UK, and OCUS Ireland entities.

Product overview

OCUS Innovation is a clinical research organization focused on ophthalmological and regulatory sciences, operating across Hong Kong, UK, and Ireland. The company operates through regional entities (OCUS HK, OCUS UK, OCUS Ireland) that collaborate to support product development and clinical research in myopia control. The core portfolio centers on atropine eye drop formulations (0.01%, 0.025%, and 0.05%) for slowing myopia progression in children, with the flagship initiative being the MODERATO Trial—a multinational clinical study evaluating higher atropine concentrations in European populations. Research activities include a separate Hong Kong-based retrospective study on 0.01% atropine conducted with HKU and CUHK.

Differentiator

Problem solved

Functional benefit

Products and services

• MODERATO Trial A randomized, blinded, placebo-controlled two-year clinical trial evaluating the efficacy of 0.025% and 0.05% atropine eye drops in slowing myopia progression in European children aged 3-17 years. The study targets 234 participants recruited across hospital and university clinical sites in the UK, Ireland, Albania, Spain, Italy, and Poland.
• Hong Kong Atropine Retrospective Study A retrospective, non-interventional, longitudinal, population-based cohort study using electronic medical records from the Eye Centres of The University of Hong Kong (HKU) and The Chinese University of Hong Kong (CUHK). It investigates safety, tolerability, and myopia progression in children aged 4-14 years prescribed 0.01% atropine eye drops between 2016 and 2023.
• 0.025% Atropine Eye Drops Higher-concentration atropine ophthalmic formulation under clinical evaluation in the MODERATO trial for slowing myopia progression in European children, building on efficacy findings from Asian ATOM and LAMP trials.
• 0.05% Atropine Eye Drops Higher-concentration atropine ophthalmic formulation under clinical evaluation in the MODERATO trial for slowing myopia progression in European children, building on efficacy findings from Asian ATOM and LAMP trials.
• 0.01% Atropine Eye Drops Low-concentration atropine ophthalmic formulation studied retrospectively in Hong Kong clinical settings for myopia progression control in children aged 4-14 years, examined via electronic medical records at HKU and CUHK Eye Centres.

Quantifiable outcome

• Less eye elongation and slower prescription increases expected in atropine groups compared to placebo

Segments1 record

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

14 partnerships are on record, tiered core.

• Moorfields Eye Hospital NHS Foundation TrustcoreStrategic or Co-development Partner · 1 March 2025UK clinical trial site for the MODERATO trial investigating atropine concentrations for myopia control in children. The London-based hospital provides clinical infrastructure and patient recruitment for the study.
• Belfast Health and Social Care TrustcoreStrategic or Co-development PartnerNorthern Ireland clinical trial site for the MODERATO trial, contributing to the European multi-site study on atropine-based myopia control.
• Aston University School of OptometrycoreStrategic or Co-development PartnerBirmingham-based academic partner providing optometry expertise and patient recruitment for the MODERATO trial in the UK.
• University Hospital Centre Mother Teresa (UHCT)coreStrategic or Co-development PartnerAlbanian clinical trial site contributing to European patient recruitment for the MODERATO atropine study in Tirana.
• Hospital Universitario Parc TaulícoreStrategic or Co-development PartnerBarcelona-based Spanish clinical trial site for the MODERATO trial investigating atropine for myopia progression control.
• Hospital Puerta del MarcoreStrategic or Co-development PartnerCádiz-based clinical trial site in Spain for the MODERATO atropine study.
• Hospital Universitario La PazcoreStrategic or Co-development PartnerMadrid-based clinical trial site contributing to the MODERATO trial on atropine-based myopia control.
• AOU Consorziale Policlinico – Ospedale Pediatrico Giovanni XXIIIcoreStrategic or Co-development PartnerBari-based pediatric hospital in Italy serving as clinical trial site for the MODERATO study.
• Fondazione IRCCS Cà Granda Ospedale Maggiore PoliclinicocoreStrategic or Co-development PartnerMilan-based clinical trial site contributing to European patient recruitment for the atropine myopia study.
• Azienda Ospedale Università PadovacoreStrategic or Co-development PartnerPadua university hospital in Italy providing clinical research infrastructure for the MODERATO trial.
• Children's Memorial Health InstitutecoreStrategic or Co-development PartnerWarsaw-based pediatric healthcare institution serving as Polish clinical trial site for the MODERATO atropine study.
• The University of Hong Kong (HKU)coreStrategic or Co-development PartnerHong Kong-based academic partner for the atropine eye drops study on myopia progression in children. HKU Eye Centre provides electronic medical records and clinical expertise with Prof. Ian C.K. Wong from Department of Pharmacology and Pharmacy serving on OCUS board.
• The Chinese University of Hong Kong (CUHK)coreStrategic or Co-development PartnerHong Kong academic partner for the retrospective cohort study on 0.01% atropine eye drops safety and tolerability. Prof. Jason C.S. Yam from Department of Ophthalmology and Visual Sciences serves on the OCUS board.
• University College CorkcoreStrategic or Co-development PartnerIrish academic partner with Dr. Suzanne McCarthy, Senior Lecturer at School of Pharmacy, supporting MODERATO trial operations in Ireland and advancing myopia control research in European children.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Bausch + Lomb: Global ophthalmic pharmaceutical and device company with interests in myopia management. Comparable as a broad incumbent in pediatric ophthalmology with adjacent myopia-control programs.
• Santen Pharmaceutical: Asia-Pacific ophthalmic pharmaceutical incumbent with established myopia-control products (e.g., atropine-based and combination therapies). Broader portfolio but directly competes in OCUS's atropine-for-myopia indication.
• Johnson & Johnson Vision: Global ophthalmic device and pharmaceutical player with myopia-management initiatives. Comparable as a broad incumbent pursuing pediatric myopia control through both contact lens and pharmaceutical pathways.
• HOYA Vision Care: Ophthalmic lens and vision-care company with myopia-management solutions (e.g., MiYOSMART spectacle lens). Competes for the same pediatric myopia-control wallet, primarily through optical interventions.
• CooperVision: Markets MiSight 1 day, the first FDA-approved contact lens for myopia control in children. Competes for the same pediatric myopia-control prescribing decision, though via an optical rather than pharmacological modality.
• AbbVie (Allergan Aesthetics eye care): Diversified biopharma with ophthalmic franchise. Comparable as a broad incumbent with the capital and regulatory infrastructure to enter or dominate the pediatric myopia pharmacotherapy market if OCUS data proves compelling.

Others

• IQVIA: Global clinical research organization providing trial operational infrastructure comparable to OCUS's CRO-style service offering. Useful as a benchmarking reference for trial-economics and CRO scalability.

Direct peers

• Eyenovia: Developer of MicroPine, a proprietary atropine delivery platform for pediatric myopia. Competes head-to-head with OCUS in the same pediatric myopia pharmacotherapy category with a more advanced clinical pipeline.
• Vyluma: Clinical-stage biopharma developing NVK002, a low-dose atropine eye drop for pediatric myopia progression. Directly comparable to OCUS on indication (myopia control), modality (atropine), and clinical-stage asset profile.
• Sydnexis: Biopharma developing SYD-101, a low-dose atropine formulation for myopia progression in children. Directly comparable on indication, modality, and formulation strategy.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OCUS Innovation